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Abstract – Lyme borreliosis is the most common vector-borne disease in the northern hemisphere. The agents of Lyme 
borreliosis are borrelia, bacteria of the family Spirochaetaceae, which are grouped in Borrelia burgdorferi sensu lato species 
complex. Borreliae are fastidious, slow-growing and biochemically inactive bacteria that need special attention and opti-
mal conditions for cultivation. The isolation of Borrelia from clinical material and their cultivation is a time-consuming 
and demanding procedure. Cultivation lasts from 9 up to 12 weeks, which is much longer than is necessary to grow most 
other human bacterial pathogens. Although B. burgdorferi sensu lato is susceptible to a wide range of antimicrobial agents 
in vitro, up to now the susceptibility of individual Borrelia species to antibiotics is defined only partially.
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INTRODUCTION
Lyme borreliosis is a multisystem disease caused by 
spirochete B. burgdorferi sensu lato that is transmit-
ted to humans by ticks of the Ixodes complex and 
is manifested with diverse clinical signs and symp-
toms and with several variations in the course of the 
disease. A complete presentation of the disease has 
been divided into three clinical stages: early infection 
manifested as skin lesion erythema migrans at the 
site of the tick bite (stage 1), followed by involvement 
of the nervous system, joints and/or heart (stage 2) 
and late involvement of the nervous system, joints 
and skin that appear within months or years (Stanek 
and Strle, 2003; Steere, 2001).
At least four B. burgdorferi sensu lato species, B. 
burgdorferi sensu stricto, B. afzelii, B. garinii, and B. 
spielmanii are pathogenic to humans in Europe; B. 
bissettii and B. lusitaniae are rarely, while B. valaisi-
ana is considered as potential cause of human dis-
ease in Europe. The only known species that causes 
human infection in North America is B. burgdor-
feri sensu stricto, while B. garinii and B. afzelii have 
been found in Asia (Bergström et al., 2002; Col-
lares-Pereira et al., 2004; Fingerle et al., 2008; Ri-
jpkema et al., 1997; Stanek and Strle, 2003; Steere, 
2001). Skin manifestations (erythema migrans and 
acrodermatitis chronica atrophicans) and nerve in-
volvement (Lyme neuroborreliosis) are frequently 
associated with B. afzelii and B. garinii respectively, 
while  joint  involvement  (Lyme  arthritis)  is  more 
often observed in the USA than in Europe and is 
associated with B. burgdorferi sensu stricto (Stanek 
and Strle, 2003; Steere, 2001; Strle et al., 1996a). In 
Europe the most frequently isolated species from 
human material is B. afzelii, followed by B. garinii, 
while B. burgdorferi sensu stricto is a rarely isolated 
species (Ružić-Sabljić et al., 2002; Stanek and Strle, 
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Geographic distribution and incidence rate
Lyme borreliosis occurs in North America (from the 
Mexican border in the south to the southern Cana-
dian provinces in the north), the whole Europe, parts 
of North Africa (Maghreb), and northern Asia (Rus-
sian Siberia and the Far East, Sakhalin, Japan, China 
and Korea). In North America, Lyme borreliosis has 
been recorded in almost all states. The existence of 
Lyme borreliosis in the southern hemisphere (South 
and Central America, Sub-Saharan Africa, southern 
Asia, Australia) has never been reliably confirmed 
(Hubálek, 2009).
The  incidence  of  Lyme  borreliosis  is  associat-
ed with the prevalence of the main vectors – ticks, 
which are classified as the Ixodes ricinus complex, 
also  called  Ixodes  persulcatus  complex  (Hubálek, 
2009; Steere et al., 2004). Species of borrelia (patho-
genic, less pathogenic and non-pathogenic Borrelia 
species) and geographical distribution of ticks are 
presented in Table 1.
About 85,000 and 19,000 (from 15,000 to 20,000) 
cases  are  reported  annually  in  Europe  and  in  the 
USA, respectively (estimated from available national 
data)  (Lindgren  and  Jaenson,  2006;  Steere,  2001). 
The highest incidence of Lyme borreliosis is in cen-
tral Europe (e.g. Slovenia, 155/100,000) and the low-
est in the UK (0.7/100,000) and Ireland (0.6/100,000) 
(Lindgren and Jaenson, 2006). 
The registration of patients with Lyme borreliosis 
is necessary in only a few European countries, and it 
is assumed that the real incidence of this disease is 
most probably higher.
Causative agent
Borreliae  are  thin,  elongated,  and  motile  bacteria 
with  7  to  11  periplasmatic  flagella,  which  are  en-
closed between the outer and cytoplasmatic mem-
branes. The cells are 8 to 22 µm long, 0.25-0.30 µm 
wide and composed of 3-10 loose coils (Barbour and 
Hayes, 1986; Preac-Mursic and Wilske, 1993). The 
helical shape of Borrelia burgdorferi sensu lato (vis-
ible in the scanning electron micrograph) is shown 
in Fig. 1 (Rosa et al., 2005).
The outer cell membrane is very fluid and con-
tains  transmembrane  and  outer  surface  proteins 
(Osp). Outer surface proteins (Osp A, Osp B, Osp C, 
Osp D, Osp E in Osp F) are lipoproteins encoded by 
the linear and circular plasmids. They are important 
for maintening the structure of the membrane, while 
some of them have a role in enzymatic reactions or 
in transport through the membrane. Osp A, Osp B, 
and Osp C are the most important antigens of Bor-
relia. On their surface are many antigenic character-
istics, which give to Borrelia the properties of hetero-
geneous bacteria (Dressler et al., 1993; Wilske et al., 
1988). In addition, the outer membrane also contains 
lipopolysaccharides that are similar to the lipopoly-
saccharides of Gram-negative bacteria (Barbour and 
Hayes, 1986; Cox et al., 1996). Different outer surface 
proteins help Borrelia in adaptation and survival in 
different arthropod and mammalian environments 
(de Silva and Fikrig, 1997). Osp A is one of the major 
outer membrane lipoproteins of Borrelia and has been 
used for serological diagnosis as well as for vaccine 
development (Hilton et al., 1996; Kramer et al. 1996). 
Fig.  1.  Scanning  electron  micrograph  of  Borrelia  burgdorferi 
sensu lato (Rosa et al., 2005)
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Antibodies directed against Osp A appear in the later 
stage of Lyme borreliosis (Wilske et al., 1996). Osp B 
has adhesive properties like Osp A, and antibodies di-
rected against this antigen appear in the late stage of 
disease (Dressler et al., 1993). Osp C is the predomi-
nant seroreactive antigen in the early stage of Lyme 
borreliosis, and important in the transmission of the 
spirochete from tick to mammal. Rapid synthesis of 
Osp C by Borrelia during tick feeding is an essential 
in the capacity of Borrelia to infect mammalian hosts, 
including humans, when transmitted by ticks, and af-
ter transmission from the tick may play a role in colo-
nization of host tissues (Schwan et al., 1995; Schwan, 
2003). The sequences of Osp C vary among strains 
and only a few of the groups of sequences are associ-
ated with dissemination, and Osp C alleles have been 
linked to infectivity as well as to invasiveness (Lagal 
et al., 2003; Seinost et al. 1999). 
Table 1. Species of borrelia and geographical distribution of ticks (Steere et al., 2004; Stanek and Strle 2003).
Borrelia species Tick (the main vector of Lyme borreliosis) Location
Pathogenic     
B. afzelii I. ricinus Europe
  I. persulcatus Asia
B. garinii I. ricinus Europe
  I. persulcatus Asia
B. burgdorferi sensu stricto  I. scapularis Eastern and central parts of North America
  I. pacificus Western part of North America
  I. ricinus Europe
B. spielmanii  I. ricinus Europe
Less pathogenic and non-pathogenic     
B. andersonii  I. dentatus Eastern part of North America
B. bissettii I. spinipalpis Western part of North America
  I. pacificus  
B. valaisiana  I. ricinus Central Europe, Ireland, Great Britain 
B. lusitaniae  I. ricinus Europe (mainly Portugal)
B. japonica I. ovatus Japan
B. tanukii  I. tanukii Japan
B. turdae  I. turdus Japan
B. sinica I. persulcatus China
Table 2. The main differences between MKP, BSK-II and BSK-H media.
Medium  Gelatin  Yeast extract Glucose (%) Rabbit serum
BSK-II present present 5 6 %  non-inactivated
MKP present non-present 3 7,2 % heat-inactivated 
BSK-H non-present present 6 6 % non-inactivated536 GORANA VEINOVIĆ ET AL.
The genome of Borrelia species consists of a lin-
ear chromosome of approximately one million base 
pairs (Mb) and various linear and circular plasmids 
(Saint Girons et al., 1992). B. burgdorferi sensu stric-
to strain B31 was the first spirochete whose complete 
genome was sequenced. The genome of this strain 
consists of a linear chromosome of 910, 725 bp and 
17 linear and circular plasmids of 533,000 bp (Fraser 
et al., 1997). 
The chromosome of Borrelia is important for the 
identification of species, and methods for identifica-
tion are based on the analysis of plasmid or chro-
mosomal DNA (e.g. restriction of entire DNA with 
different  restriction  enzymes,  hybridization,  DNA 
sequencing, etc.) (Belfaiza et al., 1993; Picken et al., 
1996; Wang et al., 1999). B. burgdorferi sensu lato 
strains differ among themselves in relation to differ-
ent plasmid profiles. They have an unusual plasmid 
content of linear and circular plasmids that may vary 
in number and size. This feature is very important 
in comparing and distinguishing strains within the 
same species (Xu and Johnson, 1995).
The spreading of Borrelia through the skin and 
other tissue is facilitated by the binding of human 
plasminogen, which can then be converted to ac-
tive plasmin. Borrelia with bound plasmin is able to 
degrade fibronectin, penetrate the endothelium, and 
activate matrix metalloprotease-9 (MMP-9), and col-
lagenase 1 (MMP-1) (Coleman et al., 1995; Coleman 
et al., 1999; Gebbia et al., 2001). 
Isolation of B. burgdorferi sensu lato from clinical 
materials and growth conditions in vitro
The isolation of Borrelia from clinical materials is a 
golden standard for confirming borrelial infection, 
especially  useful  during  the  first  several  weeks  of 
infection when serodiagnostic tests are insensitive 
(Ružić-Sabljić et al., 2006; Steere, 2001).  
Borrelia can be isolated from different clinical 
materials  such  as  skin,  blood,  cerebrospinal  fluid 
(CSF), etc. during early as well as chronic stages of 
Lyme borreliosis (Ružić-Sabljić et al., 2002; Wilske 
and Preac-Mursic, 1993). The clinical material for 
isolation must be taken from patients under aseptic 
conditions, before antimicrobial therapy, in as large 
a quantity as possible (e.g. 2 mL of CSF, 10mL of 
blood) and inoculated into the medium as soon as 
possible (Wilske and Preac-Mursic, 1993; Wilske and 
Pfister, 1995). In addition to the above-mentioned, 
temperature is very important during the transpor-
tation of clinical material from patient to laboratory. 
Room temperature was described as suitable for the 
transport of samples infected with Borrelia during the 
period from one to 11 days, while refrigerator tem-
perature (5ºC) was described as inadequate (Berger 
et al., 1992; Campbell et al., 1994).
  Isolation, as well cultivation of borrelia, is a 
demanding, time-consuming and expensive proce-
dure characterized by a modest level of sensitivity 
(Kollars et al., 1997; Maraspin et al., 2001; Nadelman 
et al., 1996; Strle et al., 1996a; Wormser et al., 2000a), 
and few laboratories are equipped to carry it out. 
The yield of Borrelia culture from clinical sam-
ples is usually low, from 20 to 90% (usually 50%) of 
skin biopsy from erythema migrans (Nowakowski et 
al., 2001; Strle et al., 1996a; Wilske and Preac-Mursic, 
1993), while the culture from blood and cerebrospi-
nal fluid (CSF) yields borrelia in less than 10% of 
samples (Maraspin et al., 2002; Wilske and Preac-
Mursic, 1993).
Borreliae are fastidious, slow-growing, and bio-
chemically inactive bacteria that need special atten-
tion and optimal conditions for cultivation, and they 
grow  best  under  anaerobic  conditions  at  30-34°C 
(Barbour and Hayes, 1986; Preac-Mursic et al., 1986; 
Preac-Mursic  and  Wilske,  1993).  Some  strains  of 
Borrelia grow well at 35-39°C, while temperatures 
of 40°C and higher reduce or prevent their growth 
(Barbour, 1984; Heroldova et al., 1998; Hubalek et al., 
1998; Reisinger et al., 1996;). Generally, low tempera-
tures (4°C) are better tolerated than high tempera-
tures (37-42ºC) (Preac-Mursic and Wilske, 1993). 
The generation time of Borrelia is long and rang-
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ents, conditions of cultivation and the adaptation of 
Borrelia to the artificial medium (Preac-Mursic and 
Wilske, 1993). Cultivation lasts from 9 to 12 weeks, 
which  is  much  longer  than  needed  to  grow  most 
other  human  bacterial  pathogens  (Ružić-Sabjić  et 
al., 2002; Wormser et al., 2000a). On the other hand, 
borrelia requires complex media for in vitro cultiva-
tion, due to their inability to synthesize any amino 
acids, nucleosides, nucleotides, fatty acids, or other 
cellular building blocks (Fraser et al., 1997). 
Many  factors  can  influence  in  vitro  Borrelia 
growth, such as medium ingredients, pH of medium, 
temperature of incubation, contaminants, sample cell 
density, the capacity of particular borrelial species to 
grow, number of different Borrelia strains in the sam-
ple, previous antibiotic therapy, local anesthesia at 
the site of skin biopsy, size of skin biopsy specimens, 
and conditions during the transport of samples to 
the laboratory (Barbour 1984; Callister et al., 1990; 
Campbell et al., 1994; Hubálek et al., 1998; Jobe et al., 
1993; Kollars et al., 1997; Pollack et al., 1993; Ružić-
Sabljić et al., 2006; Wormser et al., 2000a; Yang et al., 
2001).
Borrelia has an ability for in vitro transforma-
tion of normal, mobile spirochetes to cystic forms 
under unfavorable conditions in their environment 
(Brorson and Brorson, 1997). The authors evaluated 
the behavior of Borrelia under controlled conditions 
and Borrelia was cultivated in commercial BSK-H 
medium, which contained 6% rabbit serum, and in 
BSK-H medium without rabbit serum. In the me-
dium  without  rabbit  serum,  borreliae  were  trans-
formed into cystic forms, but after the cystic forms 
were transferred to the same culture medium with 
rabbit  serum,  they  were  transformed  into  regular, 
mobile spirochetes after 6 weeks, and their regen-
eration time was normal. This means that similar 
phenomenon may occur in vitro under other condi-
tions unfavorable for Borrelia (e.g. the presence of 
antibiotics). Similarly, when normal, mobile spiro-
chetes were inoculated into cerebrospinal fluid, the 
spirochetes were converted to cysts (spheroplast L-
forms), but when these cystic forms were transferred 
to BSK-H medium, the cysts were converted back to 
normal, mobile spirochetes after incubation. When 
neuroborreliosis is suspected, it is necessary to real-
ize that Borrelia species can be present in cystic form, 
and these cysts have to be recognized by microscopy 
(Brorson and Brorson, 1998).
Description of culture media
The preparation of culture media is demanding and 
expensive. Different culture media have been intro-
duced  and  evaluated  for  borrelial  cultivation,  but 
for routine work most frequently three liquid media 
were reported: modified Kelly-Pettenkofer (MKP), 
Barbour-Stoenner-Kelly  II  (BSK-II)  medium  and 
commercially  available  BSK-H  (Sigma,  USA)  me-
dium (Barbour 1984; Pollac et al., 1993; Preac-Mur-
sic et al., 1986;). The majority of the ingredients in 
these media are equivalent (e.g. CMRL as a source of 
amino acids, vitamins, and other factors, N-acetyl-
D-glucosamine-a precursor for bacterial cell wall bi-
osynthesis, HEPES, neopeptone, pyruvic acid, citric 
acid, bovine serum albumin, rabbit serum, etc.). 
On the other hand, media differ with regard to 
concentration, origin (diverse commercial sources), 
and the preparation of certain ingredients (Barbour, 
1984; Pollack et al., 1993; Preac-Mursic et al., 1986; 
Ružić-Sabljić et al., 2006). For example, in contrast to 
BSK-H, BSK-II and MKP contain gelatin, but MKP 
lacks yeast extract and contains a higher concentra-
tion of rabbit serum that differs in its preparation 
(7.2% heat-inactivated rabbit serum in MKP versus 
6% non-inactivated in BSK-II and BSK-H). There is 
also a difference in glucose concentration between 
the three media: 3, 5 and 6% for MKP, BSK-II, and 
BSK-H medium, respectively. The main differences 
between MKP, BSK-II and BSK-H are presented in 
Table 2. 
The source and quality of albumin and specific 
preparation of rabbit serum can influence Borrelia 
growth in vitro and some preparations of rabbit se-
rum contain antispirochetal immunoglobulin G that 
reduces or inhibits the growth of Borrelia (Pollack et 
al., 1993). Similarly, if identical BSK media contain 
different lots of bovine serum albumin from differ-538 GORANA VEINOVIĆ ET AL.
ent manufacturers, they differ in their ability to sup-
port the growth of a small number of Borrelia strains 
(Callister et al., 1990).
Borrelia strains can also grow on solid media with 
agarose to solidify the liquid media under microaer-
ophilic or anaerobic conditions (De Martino et al., 
2006; Kurtti et al., 1987; Preac-Mursic et al., 1991). 
By  using  a  solid  medium,  distinct  morphological 
variations in colonies of B. burgdorferi sensu stricto 
strains can be observed.
Three pathogenic Borrelia species (B. afzelii, B. 
garinii, and B. burgdorferi sensu stricto) grow well in 
both MKP and BSK-II media as was described previ-
ously (Ružić-Sabljić and Strle, 2004). On the other 
hand, Ružić-Sabljić et al. (2006) indicated a similar 
suitability  of  MKP  and  BSK-II  media  for  routine 
laboratory work. The authors evaluated the isolation 
rate of B. afzelii, B. garinii, and B. burgdorferi sensu 
stricto from MKP and BSK-II media and showed 
comparable Borrelia isolation rates in both media. 
Comparison of B. afzelii, B. garinii, and  
B. burgdorferi sensu stricto
B. burgdorferi sensu stricto has been described as a 
more virulent and aggressive Borrelia species than B. 
afzelii i B. garinii (Ružić-Sabljić and Strle 2004; Strle 
et al., 1999a, Strle et al., 2011). 
Ružić-Sabljić  and  Strle  (2004)  compared  the 
growth of B. afzelii, B. garinii, and B. burgdorferi sen-
su stricto in MKP and BSK-II media, and established 
that in a mixture of two species, B. burgdorferi sensu 
stricto behaves as the most aggressive species, fol-
lowed by B. garinii and at lastly B. afzelii. B. burgdor-
feri sensu stricto overgrew B. afzelii and B. garinii in 
both media, but the results were found to be statisti-
cally significant only for the MKP medium, while B. 
garinii overgrew B. afzelii but significant differences 
were established only for the BSK-II medium.
Strle et al. (1999a) compared patients in Europe 
and  USA  with  culture-confirmed  erythema  mi-
grans, and showed B. burgdorferi sensu stricto (iso-
lated from USA patients) to be more virulent than B. 
afzelii (isolated from Slovenian patients). Erythema 
migrans spreads more slowly, the duration is longer, 
and the possibility of dissemination is less common 
in European patients, unlike erythema migrans in 
USA patients, which spreads more rapidly, the dura-
tion is shorter, and it is associated with more inten-
sive inflammation and signs that often indicate the 
dissemination of Borrelia.
Similarly, in a comparison of the European and 
USA patients with culture-confirmed erythema mi-
grans, Strle et al. (2011) showed B. burgdorferi sensu 
stricto isolated from USA patients to be more viru-
lent than B. garinii isolated from Slovenian patients. 
Slovenian patients with erythema migrans caused by 
B. garinii developed larger lesions than USA patients, 
but systemic symptoms and abnormal physical find-
ings, such as fever or regional lymphadenopathy, ap-
pear more frequently in USA patients with erythema 
migrans caused by B. burgdorferi sensu stricto than 
in European patients.
Furthermore, B. burgdorferi sensu stricto induc-
es normal macrophages to secrete higher levels of 
chemokines and cytokines than B. afzelii or B. garinii, 
indicating that B. burgdorferi sensu stricto induces a 
greater inflammatory response in macrophages than 
the other two Borrelia species (Strle et al., 2009).
In vitro susceptibility of B. burgdorferi sensu lato to 
different antimicrobial agents
Many in vitro studies have been performed to find 
an optimal treatment for Lyme borreliosis. Previ-
ous  in  vitro  antimicrobial  susceptibility  studies 
have  demonstrated  the  susceptibility  of  B.  burg-
dorferi sensu lato to a broad spectrum of antimi-
crobial agents, including penicillin G, amoxicillin, 
azithromycin, erythromycin, clarithromycin, ceftri-
axone, cefuroxime, cefotaxime, doxycycline, vanco-
mycin,  gemifloxacin  etc.  (Baradaran-Dilmaghani 
and Stanek, 1996; Dever et al., 1993; Hunfeld et al., 
2000a; Hunfeld et al., 2000b; Kraiczy et al., 2001; 
Levin et al., 1993; Ružić-Sabljić et al., 2005; Sicklin-
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Published  in  vitro  susceptibility  results  on  the 
minimal inhibitory concentracion (MIC) and mini-
mal  bactericidal  concentracion  (MBC)  of  antimi-
crobial agents for borreliae are difficult to compare 
because of methodological differences. Up to now, 
broth microdilution and macrodilution methods in 
different media (MKP, Barbour-Stoener-Kelly, BSK-
II or standardized BSK-H) with various inoculum 
concentrations (104 - 107/ mL), incubation periods 
(3-7 days for MIC, 1-6 weeks for MBC) were applied. 
Samples  were  mainly  checked  for  the  presence  of 
Borrelia by the enumeration of cells and observation 
of borrelia motility using dark-field microscopy or 
by visual conformation of medium color changes in 
microtiter plates.
On the other hand, enumeration and observa-
tion of Borrelia is time-consuming and demanding, 
especially if more samples need to be checked simul-
taneously and subjectively.
Boerner  et  al.  (1995)  reported  that  the  MIC 
values  for  Borrelia  are  significantly  influenced  by 
the density of the inoculum and the mode of MIC 
determination  (microscopical  and  macroscopical 
MIC reading). The authors showed that differences 
between MIC values obtained by testing 106 versus 
107 Borrelia cells/mL were on average equivalent to 
1.2 dilution steps for the macroscopical but only 0.2 
dilution steps for the microscopical method, and that 
the high agreement of microscopical MICs has been 
due to the standardized enumeration method. Using 
an inoculum of 106 cells/mL, MICs determined mac-
roscopically (which is less time-consuming than the 
microscopical method) were significantly lower than 
MICs determined microscopically because the inoc-
ulum of 106 cells/mL was too small to induce a dis-
tinct color change and sediment formation, whereas 
borrelial  growth  was  often  detectable  microscopi-
cally. On the other hand, when using 107 cells/mL 
as the final inoculum, 75.9% of the MICs revealed 
identical values for both the macroscopical and the 
microscopical reading modes.
This discrepancy in the methodology led to a 
wide range of published MIC and MBC results. For 
example,  for  amoxicillin,  ceftriaxone,  doxycycline, 
and azithromycin the MIC varies from ≤0.03 to 4 
mg/L, from ≤0.01 to 4 mg/L, from 0.06 to 4 mg/L, 
and from 0.003 to 0.06 mg/L, respectively. Similarly, 
for  amoxicillin,  ceftriaxone,  doxycycline,  and  azi-
thromycin, the MBC varies from ≤0.03 to >16 mg/L, 
from 0.006 to 4 mg/L, from 0.4 to 32 mg/L, and from 
0.003  to  4  mg/L,  respectively.  (Baradaran-Dilma-
ghani and Stanek, 1996; Dever et al., 1992; Hunfeld 
et al., 2000a; Hunfeld et al., 2000b; Levin et al., 1993; 
Morgenstern et al., 2009; Ružić-Sabljić et al., 2005; 
Sicklinger et al., 2003). Despite the problems in the 
methodology, in vitro susceptibility testing has also 
been limited because of the small number of tested 
B. burgdorferi sensu lato strains.
Ružić-Sabljić et al. (2005) tested the susceptibility 
of B. afzelii strains to antimicrobial agents, and found 
that several isolates survived high concentrations of 
doxycycline, cefuroxime axetyl and amoxicillin and 
grew after 6 weeks but not after 3 weeks incubation. 
Their results showed that borrelia could survive ex-
posure to antibiotics in vitro, but mechanisms of re-
sistence are not obvious.
One possible explanation for the survival of Bor-
relia in the presence of antibiotics could be the abil-
ity of Borrelia to persist in a latent phase. The ability 
could enable spirochetes to survive the presence of 
antimicrobial agents in their environment and begin 
to re-grow under suitable conditions, e.g. after antibi-
otic elimination in the body or after reduction or loss 
of activity of antibiotics during a prolonged incuba-
tion period in vitro. On the other hand, Preac-Mursic 
et al. (1996b) showed that Borrelia has the ability to 
transform into a cystic, spherical form (spheroplasts, 
L-form), which may offer protection from antimi-
crobial agents, allowing them to survive unfavorable 
conditions such as the presence of antibiotics. The 
spheroplast-L-form without cell walls can be a pos-
sible reason why Borrelia can survive in an organism 
for a long time and the cell-wall-dependent antibody 
titers disappear and emerge after reversion.
Georgilis et al. (1992) reported that human skin 
fibroblasts could protect Borrelia from ceftriaxone in 540 GORANA VEINOVIĆ ET AL.
vitro. While this antibiotic lost efficiency when Bor-
relia was cultured in the presence of cells, ceftriaxone 
was lethal for spirochetes in the absence of human 
skin fibroblasts. Similarly, the study of Brouqui et al. 
(1996) confirmed the ability of Borrelia to survive 
in human cells in vitro in the presence of antimicro-
bial agents in their environment. When Borrelia was 
cultivated in an axenic medium in the presence of 
penicillin G or ceftriaxone, the number of bacteria 
decreased rapidly, whereas then they were co-culti-
vated with eukaryotic cells in the presence of peni-
cillin G or ceftriaxone, no change in the viable bor-
relial count was observed. Doxycycline and erythro-
mycin were found to act efficiently against Borrelia, 
especially when they were grown in the presence of 
eukaryotic cells. No viable Borrelia was found after 
incubation with these antibiotics, indicating no pro-
tective effect of eukaryotic cells on doxycycline and 
erythromycin actions.
In  some  studies,  antimicrobial  agents  (e.g. 
β-lactams) showed moderate or weak in vitro activ-
ity against Borrelia, but are mainly effective in vivo. 
Nevertheless, the in vitro activity of many antimicro-
bial agents against Borrelia has not always correlated 
with clinical experience (Hassler et al., 1990; Luft et 
al., 1989).
A possible interaction between the ingredients 
of media, such as bovine albumin and antimicrobial 
agents, as well as the poor chemical stability of some 
antibiotics during the prolonged incubation period 
necessary for Borrelia susceptibility testing, may lead 
to the reduction or loss of their activity (Boerner et 
al., 1995; Dever et al., 1992; Reisinger et al., 1995). 
On the other hand, inadequately prepared and stored 
antibiotic solutions may also be one of reasons for 
the weak in vitro activity of some antibiotics against 
Borrelia strains.
Before performing an antibiogram (in vitro sus-
ceptibility  testing  of  antimicrobial  agents  against 
bacteria), it is necessary to prepare and store the 
antibiotic  solution  appropriately.  Jorgensen  and 
Turnidge (2003) indicated that tubes with antimi-
crobial agents should be tightly capped and stored 
at 4 to 8°C until needed in order to minimize their 
evaporation and deterioration. The dilution of most 
antimicrobial agents should be used within 5 days 
of preparation and certain β-lactam antibiotics are 
too labile for prolonged storage in final concentra-
tion.
Dever et al. (1992) reported that penicillin con-
centration reduced during incubation period at 34°C 
in BSK-II medium. The levels of penicillin G were 
reduced to 17% and less than 2% of the initial con-
centration after 72 h and 7 days, respectively. Thus, 
concentration of penicillin was undetectable after 7 
days of incubation, while the concentration of ceftri-
axone was also diminished, but was still detectable 
(47% of the initial concentration remained) after the 
same period. Similary, Kersten et al. (1995) reported 
decreased penicillin G concentrations of about 20% 
during 24 h of incubation; at 48 h more than 60% 
of the initial concentration was detectible at all the 
tested concentrations, while the remaining concen-
trations after 72 h were 50% and 20% of the initial 
concentration. After 48 h of incubation, doxycycline 
concentrations were more than 80% of initial con-
centrations. At 72 h, drug concentrations of between 
64 and 76% of the initial values could be detected, 
indicating that doxycycline was quite stable under 
culture conditions. 
The interaction between BSK-II medium and 
penicillin G led to a decrease in efficacy of 85.8% 
of this antibiotic after 72 h of incubation at 34°C, 
while other penicillins (mezlocillin and piperacil-
lin) also showed a marked decrease with time of 
incubation. On the other hand, the activity of dox-
ycycline and erythromycin increased against Bor-
relia strains when tested in BSK-medium (Boerner 
et al., 1995).
It is important to note that the effectiveness of 
some antibiotics such as penicillin and ceftriaxone 
in vitro and in vivo is temperature-dependent (Reis-
inger et al., 1996). The in vitro susceptibility of Bor-
relia strains to penicillin and ceftriaxone increased 
up to 16-fold after raising the temperature from 36°C 
to 38°C. This means that an increase in body tem-CHARACTERISTICS OF BorrelIA SPECIES 541
perature may be beneficial during the antimicrobial 
treatment of Lyme borreliosis.
In  order  to  provide  constant  and  appropriate 
concentrations  of  antimicrobial  agents  for  a  pro-
longed incubation period, Stiernstedt et al. (1999) 
developed the dialysis culture method for the deter-
mination of MICs and MBCs of benzylpenicillin for 
Borrelia. In this method, borrelial suspensions were 
enclosed in sealed dialysis membrane bags and put 
into tubes with BSK medium with the appropriate 
two-fold serial dilution of the antibiotic, and control 
tubes  with  only  BSK  medium.  The  dialysis  mem-
brane  bags  were  transferred  every  day  for  6  days 
to new tubes with BSK medium and freshly added 
antibiotic, and the MIC was determined on day 7. 
However, a shortcoming of this method is that it is 
difficult to standardize.
Some studies reported differences in the antibi-
otic susceptibilities of pathogenic Borrelia species; 
MIC and MBC values may vary from one Borrelia 
species to another (Hunfeld et al., 2000a; Hunfeld et 
al., 2000b; Morgenstern et al., 2009; Preac-Mursic et 
al., 1996a; Sicklinger et al., 2003). In previous stud-
ies, B. afzelii and B. burgdorferi sensu stricto species 
were less susceptible to some antimicrobial agents, 
whereas B. garinii species was more susceptible than 
other Borrelia species to many antibiotics. 
In the study of Hunfeld et al. (2000a), the MICs of 
penicillin for B. afzelii isolates were ten times higher 
than those for B. burgdorferi sensu stricto, B. valai-
siana, and B. bissettii isolates, and 100 times higher 
than for other Borrelia isolates. Similary, Hunfeld et 
al. (2000b) found that the MICs of amoxicillin were 
lower for B. garinii isolates than for B. afzelii, B. burg-
dorferi  sensu  stricto,  and  B.  valaisiana,  while  the 
MICs of cefixime for B. garinii isolates proved to be 
lower than those for B. afzelii isolates.
Sicklinger et al. (2003) also reported differences 
in antibiotic susceptibility between Borrelia  species. 
B. burgdorferi sensu stricto showed higher susceptibil-
ity to amoxicillin than B. afzelii and B. garinii isolates; 
B. afzelii was more susceptible to ceftriaxone than the 
other two Borrelia species, while B. garinii proved to 
be the most susceptible to azithromycin. 
Morgenstern  et  al.  (2009)  reported  that  mac-
rolides (erythromycin and clarithromycin) and dox-
ycycline showed the highest in vitro activity against 
B. spielmanii in contrast to B. afzelii, B. garinii and 
B. burgdorferi sensu stricto species, while B. spielma-
nii was less susceptible to amoxicillin than the other 
genospecies.
Preac-Mursic et al. (1996a) investigated the kill-
ing effect in MKP medium and human serum during 
a 72 h exposure to amoxicillin, doxycycline, cefotax-
ime, ceftriaxone, azithromycin and penicillin G used 
in the treatment of Lyme borreliosis. B. afzelii and B. 
garinii strains had different reactions to the antibi-
otics; B. garinii strains appeared to be more suscep-
tible to antibiotics. Furthermore, the authors found 
that differences in antibiotic susceptibility also exist 
within a single species.
In contrast to the above-mentioned studies that 
showed differences in antibiotic susceptibility among 
Borrelia species, the study by Baradaran-Dilmaghani 
and Stanek (1996) did not. Different antimicrobial 
agents  (azithromycin,  amoxicillin,  ceftriaxone,  ce-
fotaxime,  doxycycline,  penicillin  G  sodium,  roxi-
thromycin,  and  trimethoprim-sulfamethoxazole) 
were tested against thirty B. afzelii, B. garinii and B. 
burgdorferi sensu stricto strains from various sources 
(blood, cerebrospinal fluid-CSF, heart, skin and tick). 
MIC and MBC were determined after 72 h and 96 h 
of incubation, respectively, and did not show signifi-
cant differences between the tested strains. Interest-
ingly, a difference was found only for doxycycline. 
The MICs for B. afzelii isolates were lower than for 
B. garinii isolates, unlike the study of Sicklinger et 
al. (2003) where only doxycycline did not show any 
differences in its effect on B. afzelii, B. garinii, and B. 
burgdorferi sensu stricto.
Some  studies  have  reported  that  in  relapsed 
patients  with  early  Lyme  borreliosis,  Borrelia  iso-
lates cultured after the conclusion of roxithromycin 
(Hansen et al., 1992), ceftriaxone (Pfister et al., 1991) 542 GORANA VEINOVIĆ ET AL.
and azithromycin (Hunfeld at al., 2005) treatment 
remained susceptible to these agents in vitro. On the 
other hand, Terekhova et al. (2002) reported suscep-
tibility testing of laboratory strains and clinical iso-
lates of Borrelia and demonstrated the existence of 
resistance to erythromycin in them. The results of 
this study indicated an important heterogeneity in 
the susceptibility of B. burgdorferi strains to eryth-
romycin and suggested that erythromycin resistance 
could develop in Borrelia strains isolated from Lyme 
borreliosis patients that have been pre-exposed to 
the antibiotic, based on the existence of resistant sub-
populations in vitro.
In order to overcome methodological problems, 
Hunfeld  et  al.  (2000a)  introduced  a  colorimetric 
microdilution method for in vitro susceptibility test-
ing of B. burgdorferi sensu lato against antimicrobial 
agents. For this susceptibility testing, the final inocu-
lum concentration was 106 cells/mL. This is the stand-
ardized test based upon color changes (occurring in 
the presence of phenol red) and result from the ac-
cumulation of nonvolatile acid produced by actively 
metabolizing  spirochetes  after  72  h  of  incubation. 
Growth of Borrelia was detected by software-assisted 
kinetic measurement of the decrease of absorbance. 
In this method, the growth of samples and controls 
was determined for each well, based on the decrease 
in absorbance (A 562/630) after 72 h (Et72) in comparison 
to the initial absorbance values (Et0). In mathematical 
terms, if the absorbance values at 72 h decreased 5% 
or more compared with the initial absorbance values, 
the well was considered positive for borrelial growth 
(Et72 < E 0 minus 5%). The MIC was determined as 
the lowest concentration of antimicrobial agent with 
which no such significant color shift (decline of curve) 
could be detected. Colorimetric in vitro susceptibil-
ity testing has also been used in some other studies 
(Hunfeld et al., 2000b; Hunfeld et al. 2005; Kraiczy et 
al., 2001; Morgenstern et al., 2009). This MIC method 
is reliable, reproducible and convenient and can han-
dle large numbers of isolates and antibiotics (Hunfeld 
et al., 2000a), but the problem related to its wider use 
is its unavailability to other laboratories.
Despite the fact that there are differences in the 
experimental conditions and test methods applied 
during in vitro susceptibility testing of antimicro-
bial agents against Borrelia, this bacterium highly 
susceptible to antibiotic treatment and the majority 
of patients with early Lyme borreliosis profit from 
the recommended antibiotic treatment (Girschick 
et al., 2009; Strle, 1999b; Wormser et al., 2000b). 
Treatment of early Lyme borreliosis, such as skin le-
sion erythema migrans, with β-lactam agents (such 
as  amoxicillin  and  cefuroxime)  and  tetracycline 
agents was described as very successful in >90% of 
the cases (Smith et al., 2002; Thanassi and Schoen, 
2000). About 5 to 10% of patients with erythema 
migrans fail to respond to antibiotic therapy. This 
is more common with macrolide agents than with 
β-lactam  and  tetracycline  agents  (Hansen  et  al., 
1992; Hunfeld et al., 2002; Luft et al., 1996; Smith et 
al., 2002; Wormser et al., 2000b). 
Some  patients  develop  chronic  persistent  dis-
ease, and borreliae can be isolated in spite of pre-
vious  treatment  with  antibiotics  (Maraspin  et  al., 
1995). Clinical and experimental data showed that 
after so-called adequate treatment in patients with 
Lyme borreliosis, Borrelia could persist in tissue, and 
failures of treatment have been reported for almost 
every  suitable  antimicrobial  agent  (Hassler  et  al., 
1990; Preac-Mursic et al., 1989; Preac-Mursic et al., 
1996a; Straubinger et al., 1997; Strle et al., 1993 Strle 
et al., 1996b; Wormser et al., 2003). In some cases, 
the failure of treatment could be due to irreversible 
tissue  damage  during  active  borrelial  infection  or 
inflammation in association with the infection, the 
induction of autoimmune mechanisms, and possible 
misdiagnosis (Strle, 1999b). In any case, treatment 
with antibiotics is reasonable at all stages of Lyme 
borreliosis infection and for all clinical manifesta-
tions; recommendations for the treatment have been 
reported previously (Girschick et al., 2009; Steere, 
2001; Strle, 1999b).
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